Collegium Pharmaceutical Inc (NASDAQ:COLL) Expected to Post Earnings of -$0.03 Per Share

Wall Street analysts expect Collegium Pharmaceutical Inc (NASDAQ:COLL) to report ($0.03) earnings per share (EPS) for the current quarter, Zacks reports. Six analysts have made estimates for Collegium Pharmaceutical’s earnings, with estimates ranging from ($0.23) to $0.23. Collegium Pharmaceutical reported earnings of ($0.10) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 70%. The firm is expected to issue its next earnings results on Wednesday, February 26th.

According to Zacks, analysts expect that Collegium Pharmaceutical will report full year earnings of ($0.52) per share for the current financial year, with EPS estimates ranging from ($0.88) to ($0.15). For the next year, analysts forecast that the business will post earnings of $0.20 per share, with EPS estimates ranging from ($0.57) to $0.94. Zacks’ earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Collegium Pharmaceutical.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings results on Wednesday, November 6th. The specialty pharmaceutical company reported ($0.18) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by ($0.03). Collegium Pharmaceutical had a negative return on equity of 26.10% and a negative net margin of 7.45%. The business had revenue of $72.94 million for the quarter, compared to analyst estimates of $74.32 million. During the same quarter last year, the company earned ($0.50) EPS. The business’s revenue for the quarter was up 3.9% compared to the same quarter last year.

Several research analysts have commented on COLL shares. Needham & Company LLC lowered their target price on Collegium Pharmaceutical from $33.00 to $25.00 and set a “buy” rating for the company in a research note on Wednesday, October 30th. SunTrust Banks boosted their target price on Collegium Pharmaceutical to $22.00 and gave the stock a “buy” rating in a research note on Friday. Jefferies Financial Group boosted their target price on Collegium Pharmaceutical from $26.00 to $36.00 in a research note on Thursday. ValuEngine raised Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Finally, William Blair reissued a “buy” rating on shares of Collegium Pharmaceutical in a research note on Tuesday, September 17th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $24.57.

Shares of COLL traded up $1.96 during mid-day trading on Friday, hitting $19.96. 1,220,900 shares of the company’s stock were exchanged, compared to its average volume of 378,932. The company has a quick ratio of 1.20, a current ratio of 1.25 and a debt-to-equity ratio of 0.23. The stock has a market cap of $459.95 million, a price-to-earnings ratio of -16.77 and a beta of 0.52. Collegium Pharmaceutical has a twelve month low of $10.01 and a twelve month high of $19.99. The firm has a fifty day moving average of $12.16 and a two-hundred day moving average of $12.08.

In other news, CEO Joseph Ciaffoni sold 64,821 shares of the company’s stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $18.77, for a total value of $1,216,690.17. Following the completion of the transaction, the chief executive officer now owns 242,276 shares of the company’s stock, valued at $4,547,520.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director David Hirsch sold 22,106 shares of the company’s stock in a transaction that occurred on Thursday, August 29th. The shares were sold at an average price of $11.65, for a total value of $257,534.90. Following the completion of the transaction, the director now directly owns 64,223 shares of the company’s stock, valued at approximately $748,197.95. The disclosure for this sale can be found here. Corporate insiders own 8.08% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in COLL. Janus Henderson Group PLC increased its position in Collegium Pharmaceutical by 19.1% during the 2nd quarter. Janus Henderson Group PLC now owns 4,323,555 shares of the specialty pharmaceutical company’s stock valued at $56,855,000 after purchasing an additional 693,812 shares during the period. Renaissance Technologies LLC acquired a new stake in Collegium Pharmaceutical during the 2nd quarter valued at approximately $3,210,000. Cortina Asset Management LLC increased its position in Collegium Pharmaceutical by 81.0% during the 2nd quarter. Cortina Asset Management LLC now owns 509,701 shares of the specialty pharmaceutical company’s stock valued at $6,703,000 after purchasing an additional 228,035 shares during the period. Nuveen Asset Management LLC acquired a new stake in Collegium Pharmaceutical during the 2nd quarter valued at approximately $2,622,000. Finally, BlackRock Inc. increased its position in Collegium Pharmaceutical by 7.1% during the 2nd quarter. BlackRock Inc. now owns 2,488,479 shares of the specialty pharmaceutical company’s stock valued at $32,724,000 after purchasing an additional 165,018 shares during the period. 92.17% of the stock is owned by institutional investors.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, heating, and injecting.

Recommended Story: Trade War

Get a free copy of the Zacks research report on Collegium Pharmaceutical (COLL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News